Search Legislation

The Misuse of Drugs Regulations 2001

Status:

Point in time view as at 14/11/2005.

Changes to legislation:

There are currently no known outstanding effects for the The Misuse of Drugs Regulations 2001. Help about Changes to Legislation

Close

Changes to Legislation

Revised legislation carried on this site may not be fully up to date. At the current time any known changes or effects made by subsequent legislation have been applied to the text of the legislation you are viewing by the editorial team. Please see ‘Frequently Asked Questions’ for details regarding the timescales for which new effects are identified and recorded on this site.

Regulation 3

SCHEDULE 1U.K. CONTROLLED DRUGS SUBJECT TO THE REQUIREMENTS OF REGULATIONS 14, 15, 16, 18, 19, 20, 23, 26 AND 27

1.  The following substances and products, namely -U.K.

(a)Bufotenine

  • Cannabinol

  • Cannabinol derivatives not being dronabinol or its stereoisomers

  • Cannabis and cannabis resin

  • Cathinone

  • Coca leaf

  • Concentrate of poppy-straw

  • Eticyclidine

  • Etryptamine

  • [F1Fungus (of any kind) which contains psilocin or an ester of psilocin]

  • Lysergamide

  • Lysergide and otherN-alkyl derivatives of lysergamide

  • Mescaline

  • Methcathinone

  • Psilocin

  • Raw opium

  • Rolicyclidine

  • Tenocyclidine

  • 4-Bromo-2,5-dimethoxy-a-methylphenethylamine

  • N,N-Diethyltryptamine

  • N,N-Dimethyltryptamine

  • 2,5-Dimethoxy-a,4-dimethylphenethylamine

  • N-Hydroxy-tenamphetamine

  • 4-Methyl-aminorex

(b)any compound (not being a compound for the time being specified in sub-paragraph (a) above) structurally derived from tryptamine or from a ring-hydroxy tryptamine by substitution at the nitrogen atom of the sidechain with one or more alkyl substituents but no other substituent;

(c)the following phenethylamine derivatives, namely—

  • Allyl(a-methyl-3,4-methylenedioxyphenethyl)amine

  • 2-Amino-1-(2,5-dimethoxy-4-methylphenyl)ethanol

  • 2-Amino-1-(3,4-dimethoxyphenyl)ethanol

  • Benzyl(a-methyl-3,4-methylenedioxyphenethyl)amine

  • 4-Bromo-b,2,5-trimethoxyphenethylamine

  • N-(4-sec-Butylthio-2,5-dimethoxyphenethyl)hydroxylamine

  • Cyclopropylmethyl(a-methyl-3,4-methylenedioxyphenethyl)amine

  • 2-(4,7-Dimethoxy-2,3-dihydro-1H-indan-5-yl)ethylamine

  • 2-(4,7-Dimethoxy-2,3-dihydro-1H-indan-5-yl)-1-methylethylamine

  • 2-(2,5-Dimethoxy-4-methylphenyl)cyclopropylamine

  • 2-(1,4-Dimethoxy-2-naphthyl)ethylamine

  • 2-(1,4-Dimethoxy-2-naphthyl)-1-methylethylamine

  • N-(2,5-Dimethoxy-4-propylthiophenethyl)hydroxylamine

  • 2-(1,4-Dimethoxy-5,6,7,8-tetrahydro-2-naphthyl)ethylamine

  • 2-(1,4-Dimethoxy-5,6,7,8-tetrahydro-2-naphthyl)-1-methylethylamine

  • a,a-Dimethyl-3,4-methylenedioxyphenethylamine

  • a,a-Dimethyl-3,4-methylenedioxyphenethyl(methyl)amine

  • Dimethyl(a-methyl-3,4-methylenedioxyphenethyl)amine

  • N-(4-Ethylthio-2,5-dimethoxyphenethyl)hydroxylamine

  • 4-Iodo-2,5-dimethoxy-a-methylphenethyl(dimethyl)amine

  • 2-(1,4-Methano-5,8-dimethoxy-1,2,3,4-tetrahydro-6-naphthyl)ethylamine

  • 2-(1,4-Methano-5,8-dimethoxy-1,2,3,4-tetrahydro-6-naphthyl)-1-methylethylamine

  • 2-(5-Methoxy-2,2-dimethyl-2,3-dihydrobenzo[b]furan-6-yl)-1-methylethylamine

  • 2-Methoxyethyl(a-methyl-3,4-methylenedioxyphenethyl)amine

  • 2-(5-Methoxy-2-methyl-2,3-dihydrobenzo[b]furan-6-yl)-1-methylethylamine

  • b-Methoxy-3,4-methylenedioxyphenethylamine

  • 1-(3,4-Methylenedioxybenzyl)butyl(ethyl)amine

  • 1-(3,4-Methylenedioxybenzyl)butyl(methyl)amine

  • 2-(a-Methyl-3,4-methylenedioxyphenethylamino)ethanol

  • a-Methyl-3,4-methylenedioxyphenethyl(prop-2-ynyl)amine

  • N-Methyl-N-(a-methyl-3,4-methylenedioxyphenethyl)hydroxylamine

  • O-Methyl-N-(a-methyl-3,4-methylenedioxyphenethyl)hydroxylamine

  • a-Methyl-4-(methylthio)phenethylamine

  • b,3,4,5-Tetramethoxyphenethylamine

  • b,2,5-Trimethoxy-4-methylphenethylamine

(d)any compound (not being methoxyphenamine or a compound for the time being specified in sub-paragraph (a) above) structurally derived from phenethylamine, anN-alkylphenethylamine,a-methylphenethylamine, anN-alkyl-a-methylphenethylamine,a-ethylphenethylamine, or anN-alkyl-a-ethylphenethylamine by substitution in the ring to any extent with alkyl, alkoxy, alkylenedioxy or halide substitutents, whether or not further substituted in the ring by one or more other univalent substituents;

(e)any compound (not being a compound for the time being specified in Schedule 2) structurally derived from fentanyl by modification in any of the following ways, that is to say -

(i)by replacement of the phenyl portion of the phenethyl group by any heteromonocycle whether or not further substituted in the heterocycle;

(ii)by substitution in the phenethyl group with alkyl, alkenyl, alkoxy, hydroxy, halogeno, haloalkyl, amino or nitro groups;

(iii)by substitution in the piperidine ring with alkyl or alkenyl groups;

(iv)by substitution in the aniline ring with alkyl, alkoxy, alkylenedioxy, halogeno or haloalkyl groups;

(v)by substitution at the 4-position of the piperidine ring with any alkoxycarbonyl or alkoxyalkyl or acyloxy group;

(vi)by replacement of theN-propionyl group by another acyl group;

(f)any compound (not being a compound for the time being specified in Schedule 2) structurally derived from pethidine by modification in any of the following ways, that is to say—

(i)by replacement of the l-methyl group by an acyl, alkyl whether or not unsaturated, benzyl or phenethyl group, whether or not further substituted;

(ii)by substitution in the piperidine ring with alkyl or alkenyl groups or with a propano bridge, whether or not further substituted;

(iii)by substitution in the 4-phenyl ring with alkyl, alkoxy, aryloxy, halogeno or haloalkyl groups;

(iv)by replacement of the 4-ethoxycarbonyl by any other alkoxycarbonyl or any alkoxyalkyl or acyloxy group;

(v)by formation of an N-oxide or of a quaternary base.

2.  Any stereoisomeric form of a substance specified in paragraph 1.U.K.

3.  Any ester or ether of a substance specified in paragraph 1 or 2.U.K.

4.  Any salt of a substance specified in any of paragraphs 1 to 3.U.K.

5.  Any preparation or other product containing a substance or product specified in any of paragraphs 1 to 4, not being a preparation specified in Schedule 5.U.K.

Regulation 3

SCHEDULE 2U.K. CONTROLLED DRUGS SUBJECT TO THE REQUIREMENTS OF REGULATIONS 14, 15, 16, 18, 19, 20, 21, 23, 26 AND 27

1.  The following substances and products, namely—U.K.

  • Acetorphine

  • Alfentanil

  • Allylprodine

  • Alphacetylmethadol

  • Alphameprodine

  • Alphamethadol

  • Alphaprodine

  • Anileridine

  • Benzethidine

  • Benzylmorphine (3-benzylmorphine)

  • Betacetylmethadol

  • Betameprodine

  • Betamethadol

  • Betaprodine

  • Bezitramide

  • Carfentanil

  • Clonitazene

  • Cocaine

  • Desomorphine

  • Dextromoramide

  • Diamorphine

  • Diampromide

  • Diethylthiambutene

  • Difenoxin

  • Dihydrocodeinone O-carboxymethyloxime

  • [F2Dihydroetorphine]

  • Dihydromorphine

  • Dimenoxadole

  • Dimepheptanol

  • Dimethylthiambutene

  • Dioxaphetyl butyrate

  • Diphenoxylate

  • Dipipanone

  • Dronabinol

  • Drotebanol

  • Ecgonine, and any derivative of ecgonine which is convertible to ecgonine or to cocaine

  • Ethylmethylthiambutene

  • Etonitazene

  • Etorphine

  • Etoxeridine

  • Fentanyl

  • Furethidine

  • Hydrocodone

  • Hydromorphinol

  • Hydromorphone

  • Hydroxypethidine

  • Isomethadone

  • Ketobemidone

  • Levomethorphan

  • Levomoramide

  • Levophenacylmorphan

  • Levorphanol

  • Lofentanil

  • Medicinal opium

  • Metazocine

  • Methadone

  • Methadyl acetate

  • Methyldesorphine

  • Methyldihydromorphine (6-methyldihydromorphine)

  • Metopon

  • Morpheridine

  • Morphine

  • Morphine methobromide, morphine N-oxide and other pentavalent nitrogen morphine derivatives

  • Myrophine

  • Nicomorphine

  • Noracymethadol

  • Norlevorphanol

  • Normethadone

  • Normorphine

  • Norpipanone

  • Oxycodone

  • Oxymorphone

  • Pethidine

  • Phenadoxone

  • Phenampromide

  • Phenazocine

  • Phencyclidine

  • Phenomorphan

  • Phenoperidine

  • Piminodine

  • Piritramide

  • Proheptazine

  • Properidine

  • Racemethorphan

  • Racemoramide

  • Racemorphan

  • [F3Remifentanil]

  • Sufentanil

  • Thebacon

  • Thebaine

  • Tilidate

  • Trimeperidine

  • Zipeprol

  • 4-Cyano-2-dimethylamino-4,4-diphenylbutane

  • 4-Cyano-1-methyl-4-phenylpiperidine

  • 2-Methyl-3-morpholino-1,1-diphenylpropane-carboxylic acid

  • a-Methylphenethylhydroxylamine

  • 1-Methyl-4-phenylpiperidine-4-carboxylic acid

  • 4-Phenylpiperidine-4-carboxylic acid ethyl ester

Textual Amendments

2.  Any stereoisomeric form of a substance specified in paragraph 1 not being dextromethorphan or dextrorphan.U.K.

3.  Any ester or ether of a substance specified in paragraph 1 or 2, not being a substance specified in paragraph 6.U.K.

4.  Any salt of a substance specified in any of paragraphs 1 to 3.U.K.

5.  Any preparation or other product containing a substance or product specified in any of paragraphs 1 to 4, not being a preparation specified in Schedule 5.U.K.

6.  The following substances and products, namely—U.K.

AcetyldihydrocodeineMethaqualone
AmphetamineMethylamphetamine
CodeineMethylphenidate
DextropropoxypheneNicocodine
DihydrocodeineNicodicodine (6-nicotinoyldihydrocodeine)
Ethylmorphine (3-ethylmorphine)Norcodeine
FenethyllinePhenmetrazine
GlutethimidePholcodine
LefetaminePropiram
MecloqualoneQuinalbarbitone

7.  Any stereoisomeric form of a substance specified in paragraph 6.U.K.

8.  Any salt of a substance specified in paragraph 6 or 7.U.K.

9.  Any preparation or other product containing a substance or product specified in any of paragraphs 6 to 8, not being a preparation specified in Schedule 5.U.K.

Regulation 3

SCHEDULE 3U.K. CONTROLLED DRUGS SUBJECT TO THE REQUIREMENTS OF REGULATIONS 14, 15 (EXCEPT TEMAZEPAM), 16, 18, 22, 23, 24, 26 AND 27

1.  The following substances, namely—U.K.

(a)

BenzphetamineMephentermine
BuprenorphineMeprobamate
CathineMethylphenobarbitone
ChlorphentermineMethyprylone
DiethylpropionPentazocine
EthchlorvynolPhendimetrazine
EthinamatePhentermine
FlunitrazepamPipradrol
MazindolTemazepam

(b)any 5, 5 disubstituted barbituric acid not being quinalbarbitone.

2.  Any stereoisomeric form of a substance specified in paragraph 1 not being phenylpropanolamine.U.K.

3.  Any salt of a substance specified in paragraph 1 or 2.U.K.

4.  Any preparation or other product containing a substance specified in any of paragraphs 1 to 3, not being a preparation specified in Schedule 5.U.K.

Regulation 3

SCHEDULE 4U.K.

PART IU.K. CONTROLLED DRUGS SUBJECT TO THE REQUIREMENTS OF REGULATIONS 22, 23, 26 AND 27

1.  The following substances and products, namely—U.K.

  • Alprazolam

  • Aminorex

  • Bromazepam

  • Brotizolam

  • Camazepam

  • Chlordiazepoxide

  • Clobazam

  • Clonazepam

  • Clorazepic acid

  • Clotiazepam

  • Cloxazolam

  • Delorazepam

  • Diazepam

  • Estazolam

  • Ethyl loflazepate

  • Fencamfamin

  • Fenproporex

  • Fludiazepam

  • Flurazepam

  • Halazepam

  • Haloxazolam

  • [F44-Hydroxy-n-butyric acid]

  • Ketazolam

  • Loprazolam

  • Lorazepam

  • Lormetazepam

  • Medazepam

  • Mefenorex

  • Mesocarb

  • Midazolam

  • Nimetazepam

  • Nitrazepam

  • Nordazepam

  • Oxazepam

  • Oxazolam

  • Pemoline

  • Pinazepam

  • Prazepam

  • Pyrovalerone

  • Tetrazepam

  • Triazolam

  • N-Ethylamphetamine

  • [F5Zolpidem]

Textual Amendments

F4Words in Sch. 4 Pt. 1 para. 1 inserted (1.7.2003) by The Misuse of Drugs (Amendment) Regulations 2003 (S.I. 2003/1432), regs. 1, 2(3)(a)

F5Word in Sch. 4 Pt. 1 para. 1 inserted (1.7.2003) by The Misuse of Drugs (Amendment) Regulations 2003 (S.I. 2003/1432), regs. 1, 2(3)(b)

2.  Any stereoisomeric form of a substance specified in paragraph 1.U.K.

3.  Any salt of a substance specified in paragraph 1 or 2.U.K.

4.  Any preparation or other product containing a substance or product specified in any of paragraphs 1 to 3, not being a preparation specified in Schedule 5.U.K.

PART IIU.K. CONTROLLED DRUGS EXCEPTED FROM THE PROHIBITION ON POSSESSION WHEN IN THE FORM OF A MEDICINAL PRODUCT; EXCLUDED FROM THE APPLICATION OF OFFENCES ARISING FROM THE PROHIBITION ON IMPORTATION AND EXPORTATION WHEN IMPORTED OR EXPORTED IN THE FORM OF A MEDICINAL PRODUCT BY ANY PERSON FOR ADMINISTRATION TO HIMSELF; AND SUBJECT TO THE REQUIREMENTS OF REGULATIONS 22, 23, 26 AND 27

1.  The following substances, namely—U.K.

  • [F64-Androstene-3, 17-dione]

  • [F65-Androstene-3, 17 diol]

  • Atamestane

  • Bolandiol

  • Bolasterone

  • Bolazine

  • Boldenone

  • Bolenol

  • Bolmantalate

  • Calusterone

  • 4-Chloromethandienone

  • Clostebol

  • Drostanolone

  • Enestebol

  • Epitiostanol

  • Ethyloestrenol

  • Fluoxymesterone

  • Formebolone

  • Furazabol

  • Mebolazine

  • Mepitiostane

  • Mesabolone

  • Mestanolone

  • Mesterolone

  • Methandienone

  • Methandriol

  • Methenolone

  • Methyltestosterone

  • Metribolone

  • Mibolerone

  • Nandrolone

  • [F719-Nor-4-Androstene-3, 17-dione]

  • [F719-Nor-5-Androstene-3, 17 diol]

  • Norboletone

  • Norclostebol

  • Norethandrolone

  • Ovandrotone

  • Oxabolone

  • Oxandrolone

  • Oxymesterone

  • Oxymetholone

  • Prasterone

  • Propetandrol

  • Quinbolone

  • Roxibolone

  • Silandrone

  • Stanolone

  • Stanozolol

  • Stenbolone

  • Testosterone

  • Thiomesterone

  • Trenbolone

Textual Amendments

F6Words in Sch. 4 Pt. 2 para. 1 inserted (1.7.2003) by The Misuse of Drugs (Amendment) Regulations 2003 (S.I. 2003/1432), regs. 1, 2(4)(a)

F7Words in Sch. 4 Pt. 2 para. 1 inserted (1.7.2003) by The Misuse of Drugs (Amendment) Regulations 2003 (S.I. 2003/1432), regs. 1, 2(4)(b)

2.  Any compound (not being Trilostane or a compound for the time being specified in paragraph 1 of this Part of this Schedule) structurally derived from 17-hydroxyandrostan-3-one or from 17-hydroxyestran-3-one by modification in any of the following ways, that is to say -U.K.

(a)by further substitution at position 17 by a methyl or ethyl group;

(b)by substitution to any extent at one or more of positions 1, 2, 4, 6, 7, 9, 11 or 16, but at no other position;

(c)by unsaturation in the carbocyclic ring system to any extent, provided that there are no more than two ethylenic bonds in any one carbocyclic ring;

(d)by fusion of ring A with a heterocyclic system.

3.  Any substance which is an ester or ether (or, where more than one hydroxyl function is available, both an ester and an ether) of a substance specified in paragraph 1 or described in paragraph 2 of this Part of this Schedule.U.K.

4.  The following substances, namely—U.K.

Chorionic Gonadotrophin (HCG)

Clenbuterol

Non-human chorionic gonadotrophin

Somatotropin

Somatrem

Somatropin

5.  Any stereoisomeric form of a substance specified or described in any of paragraphs 1 to 4 of this Part of this Schedule.U.K.

6.  Any salt of a substance specified or described in any of paragraphs 1 to 5 of this Part of this Schedule.U.K.

7.  Any preparation or other product containing a substance or product specified or described in any of paragraphs 1 to 6 of this Part of this Schedule, not being a preparation specified in Schedule 5.U.K.

Regulation 3

SCHEDULE 5U.K. CONTROLLED DRUGS EXCEPTED FROM THE PROHIBITION ON IMPORTATION, EXPORTATION AND POSSESSION AND SUBJECT TO THE REQUIREMENTS OF REGULATIONS 24 AND 26

1.—(1) Any preparation of one or more of the substances to which this paragraph applies, not being a preparation designed for administration by injection, when compounded with one or more other active or inert ingredients and containing a total of not more than 100 milligrams of the substance or substances (calculated as base) per dosage unit or with a total concentration of not more than 2.5% (calculated as base) in undivided preparations.U.K.

(2) The substances to which this paragraph applies are acetyldihydrocodeine, codeine, dihydrocodeine, ethylmorphine, nicocodine, nicodicodine (6-nicotinoyldihydrocodeine), norcodeine and pholcodine and their respective salts.

F82.  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .U.K.

3.  Any preparation of medicinal opium or of morphine containing (in either case) not more than 0.2% of morphine calculated as anhydrous morphine base, being a preparation compounded with one or more other active or inert ingredients in such a way that the opium or, as the case may be, the morphine cannot be recovered by readily applicable means or in a yield which would constitute a risk to health.U.K.

4.  Any preparation of dextropropoxyphene, being a preparation designed for oral administration, containing not more than 135 milligrams of dextropropoxyphene (calculated as base) per dosage unit or with a total concentration of not more than 2.5% (calculated as base) in undivided preparations.U.K.

5.  Any preparation of difenoxin containing, per dosage unit, not more than 0.5 milligrams of difenoxin and a quantity of atropine sulphate equivalent to at least 5% of the dose of difenoxin.U.K.

6.  Any preparation of diphenoxylate containing, per dosage unit, not more than 2.5 milligrams of diphenoxylate calculated as base, and a quantity of atropine sulphate equivalent to at least 1% of the dose of diphenoxylate.U.K.

7.  Any preparation of propiram containing, per dosage unit, not more than 100 milligrams of propiram calculated as base and compounded with at least the same amount (by weight) of methylcellulose.U.K.

8.  Any powder of ipecacuanha and opium comprising—U.K.

  • 10% opium, in powder,

  • 10% ipecacuanha root, in powder, well mixed with

  • 80% of any other powdered ingredient containing no controlled drug.

9.  Any mixture containing one or more of the preparations specified in paragraphs 1 to 8, being a mixture of which none of the other ingredients is a controlled drug.U.K.

Regulation 19

SCHEDULE 6U.K. FORM OF REGISTER

PART IU.K. Entries to be made in case of obtaining

Date on which supply receivedNameAddressAmount obtainedForm in which obtained
of person or firm from whom obtained

PART IIU.K. Entries to be made in case of supply

Date on which transaction effectedNameAddressParticulars as to licence or authority of person or firm supplied to be in possessionAmount suppliedForm in which supplied
of person or firm supplied

Regulation 28

SCHEDULE 7U.K. REGULATIONS REVOKED

Regulations revokedReferences
The Misuse of Drugs Regulations 1985S.I. 1985/2066
The Misuse of Drugs (Amendment) Regulations 1986S.I. 1986/2330
The Misuse of Drugs (Amendment) Regulations 1988S.I. 1988/916
The Misuse of Drugs (Amendment) Regulations 1989S.I. 1989/1460
The Misuse of Drugs (Amendment) Regulations 1990S.I. 1990/2630
The Misuse of Drugs (Amendment) Regulations 1995S.I. 1995/2048
The Misuse of Drugs (Amendment No. 2) Regulations 1995S.I. 1995/3244
The Misuse of Drugs (Amendment) Regulations 1996S.I. 1996/1597
The Misuse of Drugs (Amendment) Regulations 1998S.I. 1998/882
The Misuse of Drugs (Amendment) Regulations 1999S.I. 1999/1404

Regulations 8(8) and 9(8)

[F9SCHEDULE 8U.K.

1.  Any of the following persons may supply or administer a specified controlled drug under a patient group direction, namely—U.K.

(a)a person who holds a certificate of proficiency in ambulance paramedic skills issued by, or with the approval of, the Secretary of State, or a person who is a state registered paramedic;

F10(b). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(c)a registered midwife;

(d)a registered ophthalmic optician;

(e)a state registered chiropodist;

(f)a person who is registered in the register of orthoptists maintained by the Health Professions Council pursuant to paragraph 11 of Schedule 2 to the Health Professions Order (a state registered orthoptist);

(g)a person who is registered in the register of physiotherapists maintained by the Health Professions Council pursuant to paragraph 11 of Schedule 2 to the Health Professions Order (a state registered physiotherapist);

(h)a person who is registered in the register of radiographers maintained by the Health Professions Council pursuant to paragraph 11 of Schedule 2 to the Health Professions Order (a state registered radiographer).]

Back to top

Options/Help

Print Options

Close

Legislation is available in different versions:

Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.

Original (As Enacted or Made): The original version of the legislation as it stood when it was enacted or made. No changes have been applied to the text.

Point in Time: This becomes available after navigating to view revised legislation as it stood at a certain point in time via Advanced Features > Show Timeline of Changes or via a point in time advanced search.

Close

See additional information alongside the content

Geographical Extent: Indicates the geographical area that this provision applies to. For further information see ‘Frequently Asked Questions’.

Show Timeline of Changes: See how this legislation has or could change over time. Turning this feature on will show extra navigation options to go to these specific points in time. Return to the latest available version by using the controls above in the What Version box.

Close

Opening Options

Different options to open legislation in order to view more content on screen at once

Close

More Resources

Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:

  • the original print PDF of the as enacted version that was used for the print copy
  • lists of changes made by and/or affecting this legislation item
  • confers power and blanket amendment details
  • all formats of all associated documents
  • correction slips
  • links to related legislation and further information resources
Close

Timeline of Changes

This timeline shows the different points in time where a change occurred. The dates will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. The first date in the timeline will usually be the earliest date when the provision came into force. In some cases the first date is 01/02/1991 (or for Northern Ireland legislation 01/01/2006). This date is our basedate. No versions before this date are available. For further information see the Editorial Practice Guide and Glossary under Help.

Close

More Resources

Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:

  • the original print PDF of the as made version that was used for the print copy
  • correction slips

Click 'View More' or select 'More Resources' tab for additional information including:

  • lists of changes made by and/or affecting this legislation item
  • confers power and blanket amendment details
  • all formats of all associated documents
  • links to related legislation and further information resources